Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jun 26;10:916. doi: 10.3389/fonc.2020.00916

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Deng, Zhang, Zeng, Xu, Huang and Wang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Kaplan–Meier survival analysis of breast cancer patients based on CORO2A expression level. (A) Comparison of overall survival (OS) between patients with CORO2A high and low expression levels in 1,087 breast cancer patients. (B) Comparison of relapse free survival (RFS) between patients with CORO2A high and low expression levels in 912 breast cancer patients. (C) Comparison of overall survival (OS) between patients with CORO2A high and low expression levels in 135 TNBC patients. (D) Comparison of relapse free survival (RFS) between patients with CORO2A high and low expression levels in 105 TNBC patients. (E) Comparison of overall survival (OS) between patients with CORO2A high and low expression levels in 681 luminal breast cancer patients. (F) Comparison of relapse free survival (RFS) between patients with CORO2A high and low expression levels in 545 luminal breast cancer patients. The samples with absent relapse free survival (RFS) time are removed in advance, when comparing the relapse free survival (RFS) between patients with CORO2A high and low expression levels.